CTI BioPharma Corp. (CTIC) Declines -1.149% on Dec 7

December 7, 2017 - By Dolores Ford

Shares of CTI BioPharma Corp. (BIT:CTIC) last traded at 2.236, representing a move of -1.149%, or -0.026 per share, on volume of 34,123 shares. After opening the trading day at 2.242, shares of CTI BioPharma

Corp. traded in a close range. CTI BioPharma Corp. currently has a total float of shares and on average sees 15,163 shares exchange hands each day. The stock now has a 52-week low of 2.236 and high of 42.52.

FTSE MIB (Milano Italia Borsa) Index: Driving Italy Economy

FTSE MIB Index is the equity index of 40 largest, most active and most liquid stocks on Italy’s stock market. And CTI BioPharma Corp. works with them as well. The index is market capitalization-weighted and free-floated adjusted.

FTSE MIB replaced MIB-30 in 2004. The Standard & Poor’s operated the index until June 2009 when it relinquished the administration of the benchmark index to FTSE Group, a wholly owned subsidiary of London Stock Exchange Group, which is also the parent company of Borsa Italiana, the nation stock exchange in Italy. CTI BioPharma Corp. prefer to appear at both markets.

FTSE MIB index hit a record high of 50108.56 points in March 2000. The index reached its lowest mark on record of 12362.50 points in July 2012 as fears over Spain’s debt crisis and rising cost of borrowing in Europe rattled the stock market in the region.

Components of FTSE MIB represent sectors such as Energy, Financials, Mining, Manufacturing and Telecommunications. The index accounts for 80% of the total market cap of Italia Borsa stock exchange.

FTSE MIB is reshuffled quarterly where components that have fallen short of inclusion requirements are dropped and newly qualified stocks added. But companies must meet certain stringent eligibility requirements before their stocks can be added in the index.

Rebalancing of FTSE MIB is also done to reflect the changes in the market cap of its constituents, which may come as a result of new shares being issued or debt being converted to stock.

The stock market

Italia Borsa is Italy’s main stock of Italian companies and it’s fondly known to as Piazza Affari, referring to its Milan headquarters building called Palazzo Mezzanotte.

Italia Borsa was established in February 1808. Until 1998 when the exchange was sold to a group of banks, it operated as a public entity from its inception. The exchange was acquired by London Stock Exchange group in an all-stock deal in 2007. Following the acquisition, Italia Borsa was merged with the London Stock Exchange. Other than stocks, Italia Borsa is also a platform for trading other securities such as bonds, including Eurobonds.

Trading hours

Italia Borsa is open all weekdays except on holidays. The market is closed on weekends. Trading on Italia Borsa begins with a pre-market session that runs between 8.00 a.m. and 9.00 a.m. Regular trading session on the platform starts at 9.00 a.m. and continues until 5.30 p.m. On the back of the regular trading comes post-market session that begins at 6.00 p.m. and runs until 8.30 p.m. That is the time to stop the trading day for CTI BioPharma Corp..

The long trading hours means that the exchange is accommodative for a variety of investors because there is ample room to schedule trading hours, especially for overseas investors who may be in different time zones.

Italia Borsa uses electronic trading system and more than 130 domestic and foreign brokers operate on the platform. More than 340 companies are listed on Italia Borsa.

Interest building up for Italian stocks

Italian stocks are heating up lately as investors take notice of the country’s improving growth prospects. Some investors are betting that Italy might benefit from the Brexit fallout as some of the companies leaving the U.K. move to pitch tents in the country and create employment. Increased employment and improving incomes should boost consumer purchasing power and drive up company earnings. Consumers are interested in the reliability of CTI BioPharma Corp..

More notable recent CTI BioPharma Corp. (BIT:CTIC) news were published by: Seekingalpha.com which released: “CTI Biopharma’s Pacritinib: Where We Stand Today” on August 14, 2017, also Fool.com with their article: “Why CTI BioPharma Corp. Stock Popped Today” published on January 05, 2017, Prnewswire.com published: “CTI BioPharma Announces European Medicines Agency Validation of Pacritinib …” on July 13, 2017. More interesting news about CTI BioPharma Corp. (BIT:CTIC) were released by: Prnewswire.com and their article: “CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017” published on April 25, 2017 as well as Seekingalpha.com‘s news article titled: “CTI BioPharma’s (CTIC) CEO Adam Craig on Q3 2017 Results – Earnings Call …” with publication date: November 06, 2017.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company has market cap of 96.49 million EUR. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. It currently has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>